Zeneca Files NDA for Arimidex

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application (NDA) for the use of Arimidex (anastrozole) tablets for the treatment of advanced breast cancer in postmenopausal women who have progressed following therapy with tamoxifen (Nolvadex).

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application(NDA) for the use of Arimidex (anastrozole) tablets for the treatmentof advanced breast cancer in postmenopausal women who have progressedfollowing therapy with tamoxifen (Nolvadex).

Arimidex, a nonsteroidal compound, is one of the first of a newclass of selective oral aromatase inhibitors, designed to reducethe production of estrogen. The NDA is based on randomized, controlledtrials involving 764 women with advanced breast cancer, the companysaid.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Related Content